Vaxart, Inc. (NASDAQ:VXRT) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 19.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,449,362 shares of the biotechnology company's stock after purchasing an additional 1,404,391 shares during the quarter. Vanguard Group Inc. owned about 4.78% of Vaxart worth $10,984,000 as of its most recent SEC filing.

Separately, PFG Investments LLC acquired a new stake in shares of Vaxart in the 1st quarter valued at about $38,000. Institutional investors own 18.05% of the company's stock.

Vaxart Stock Performance

NASDAQ:VXRT traded up $0.15 on Thursday, hitting $0.74. The stock had a trading volume of 7,490,827 shares, compared to its average volume of 2,801,858. Vaxart, Inc. has a 1 year low of $0.52 and a 1 year high of $1.54. The firm's fifty day simple moving average is $0.67 and its two-hundred day simple moving average is $0.90. The stock has a market cap of $131.44 million, a P/E ratio of -1.40 and a beta of 0.65.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The business had revenue of $6.40 million for the quarter, compared to the consensus estimate of $65.70 million. Vaxart had a negative return on equity of 121.06% and a negative net margin of 920.00%. During the same quarter last year, the business posted ($0.16) earnings per share. Equities research analysts predict that Vaxart, Inc. will post -0.55 EPS for the current year.

Analyst Ratings Changes

Separately, Oppenheimer assumed coverage on Vaxart in a research note on Thursday. They set an "outperform" rating and a $4.00 price target on the stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.